News & events.

Our news.

Filter by Category
Filter by Year
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
News
January 9, 2022
2022

AbCellera’s statement on the neutralization activity of its monoclonal antibody therapies against the Omicron variant of concern

Read article
News
December 7, 2021
2021

AbCellera Announces Changes to Its Board of Directors

Read article
News
December 3, 2021
2021

AbCellera-Discovered Bamlanivimab Together with Etesevimab Authorized as the First and Only Antibody Therapy for Emergency Use in COVID-19 Patients Under the Age of 12

Read article
News
December 2, 2021
2021

AbCellera Announces the Appointment of Neil Aubuchon as Chief Commercial Officer

Read article
News
November 4, 2021
2021

AbCellera Announces Virtual Presentations at Investor Conferences in November

Read article
Event
November 4, 2021
2021

PepTalk 2022

Read article
Event
November 4, 2021
2021

European Antibody Therapeutics Xchange 2021

Read article
News
November 2, 2021
2021

Lilly to Supply 614,000 Additional Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab to the U.S. Government for the Treatment or Post-Exposure Prevention of COVID-19

Read article
News
October 14, 2021
2021

AbCellera to Report Third Quarter 2021 Financial Results on November 9, 2021

Read article
News
September 22, 2021
2021

AbCellera and Everest Medicines Announce Multi-Target Collaboration to Advance New Antibody Therapies

Read article